■5-氟尿嘧啶(5-FU)的血浆浓度受多种因素的影响,从而限制了其功效。目前基于体表面积(BSA)的治疗方案剂量与毒性增加有关,有时与药物暴露不足有关。
■该研究旨在开发一种体外检测方法,以监测5-氟尿嘧啶在癌症患者血液样本中的治疗效果,专注于药代动力学,以提高治疗精度。
■根据标准确定药物水平,质量控制,和使用蛋白质沉淀的实验样品,液-液萃取,并使用具有等度程序的C18分析柱进行分离。
■在EXP-1A中,5-氟尿嘧啶的平均浓度为1.15μg/ml;在EXP-1B中,它是1.16μg/ml,而在EXP-1C中,平均浓度为0.9μg/ml。含有DPD灭活剂和EXP-1C(没有DPD灭活剂)的实验样品之间的平均5-氟尿嘧啶浓度的百分比差异对于EXP-1A高21.5%,对于EXP-1B高0.68%。在实验的第二阶段,与不含DPD灭活剂的样品相比,含有DPD灭活剂的样品中5-氟尿嘧啶的总体稳定性优于24.5%.
■已开发出一种改进的提取技术,可准确测量血液中的5-氟尿嘧啶浓度,通过添加DPD灭活剂来保持其稳定性和浓度。
UNASSIGNED: The plasma concentration of 5-Fluorouracil (5-FU) is affected by numerous factors, thereby limiting its efficacy. The current therapeutic regimen\'s doses based on body surface area (BSA) are linked to increased toxicity and sometimes inadequate drug exposure.
UNASSIGNED: The study aims to develop an in-vitro assay to monitor 5-Fluorouracil\'s therapeutic efficacy in cancer patients\' blood samples, focusing on pharmacokinetics to improve therapy precision.
UNASSIGNED: Drug levels were determined from standards, quality controls, and experimental samples using protein precipitation, liquid-liquid extraction, and separation using a C18 analytical column with an isocratic program.
UNASSIGNED: In EXP-1A, the mean concentration of 5-Fluorouracil was 1.15 μg/ml; in EXP-1B, it was 1.16 μg/ml, while in EXP-1C, the mean concentration was 0.9 μg/ml. The percentage difference in mean 5-Fluorouracil concentration between the experiment sample containing a DPD inactivator and EXP-1C (without a DPD inactivator) was 21.5 % higher for EXP-1A and 0.68 % higher for EXP-1B. In the second phase of the experiment, the overall stability of 5-Fluorouracil in samples containing a DPD inactivator was 24.5 % superior compared to samples without a DPD inactivator.
UNASSIGNED: A modified extraction technique has been developed to accurately measure 5-Flourouracil concentration in blood, preserving its stability and concentration by adding a DPD inactivator.